Back

Comparison of ridaforolimus-eluting and zotarolimus-eluting coronary stents: 5-Year outcomes from the BIONICS and NIREUS trials

1 September 2024 (17:50 - 18:00)
Organised by: Logo
Congress Presentation Part of: Decision-making for revascularisation of multivessel disease Devices ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Lior Zornitzki

Tel Aviv Sourasky Medical Center, Tel Aviv (Israel)

5 More presentations in this session

Presentation thumbnail
Clinical outcome based on functional complete revascularization in patients with three-vessel coronary artery disease: The FAME 3 Trial
Doctor H. Otsuki (Stanford, US)
Abstract Slides Video
Presentation thumbnail
Performance and safety of complex percutaneous coronary intervention in centres without on-site cardiac surgery: a multi-centre australian registry study.
Doctor N. Dayawansa (Melbourne, AU)
Abstract Slides Video
Presentation thumbnail
Percutaneous coronary intervention versus coronary arterial bypass grafting in patients with left main coronary artery disease and chronic kidney disease: a systematic review and meta-analysis
Doctor I. Gialamas (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Impact of preoperative quantitative flow ratio on long term coronary artery bypass grafts patency
Doctor J. Andreka (Graz, AT)
Abstract Slides Video
Presentation thumbnail
Ten-year comparative long-term outcomes of PCI versus CABG in multi-vessel coronary artery disease
Professor S. Sung (Taipei, TW)
Abstract Slides Video

Access the full session

Session thumbnail
Decision-making for revascularisation of multivessel disease
Video

The Event

Event poster

ESC Congress 2024

1 September 2024 17:50 CET
You may be interested in
thumbnail
Congress Presentation
Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents
thumbnail
Congress Session
Late-breaking science on acute coronary syndromes
thumbnail
Congress Session
Clinical trial updates on intervention and acute coronary syndromes

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources